BioRestorative Therapies secures $1M revolving credit facility from Bowery Group
What's the deal? BioRestorative TherapiesDealroom has a profile for this one. Try Dealroom → (NASDAQ: BRTX), a clinical-stage biotech company, has entered into a $1,000,000 revolving credit facility with Bowery Group LLC. The post-IPO debt arrangement carries a 12% annual interest rate — rising to 16% in default — and matures one year from closing.
The proceeds will fund general corporate purposes, including expenses tied to a planned public equity offering of at least $5M. As part of the deal, Bowery Group receives a right of first refusal on any future debt financing during the facility's term.
Why now? BioRestorative needs near-term liquidity to bridge its way to a larger capital raise. The credit facility is explicitly structured to support the company's pursuit of a qualified public equity offering — suggesting it needs working capital now to prepare for that bigger fundraise.
What could go wrong? The deal comes with strings attached. The agreement restricts BioRestorative from amending its organisational documents, repurchasing equity, paying dividends, or entering related-party transactions without lender consent. These covenants could constrain the company's strategic flexibility.
If the planned equity offering goes ahead, existing shareholders face dilution. If it doesn't, the company is left servicing 12% debt with limited room to manoeuvre — and faces a 16% default rate if things go sideways.
The facility is unsecured, meaning Bowery Group has no claim on specific assets, but the agreement defines multiple events of default including bankruptcy, breach of representations, and material adverse changes.
The signal: BioRestorative Therapies remains classified as an early-stage company on Dealroom despite being publicly listed on NASDAQ — a reminder that a stock ticker doesn't guarantee access to favourable financing. A clinical-stage biotech accepting 12% interest on a modest $1M facility, while granting a right of first refusal on future debt, reflects the constrained capital environment facing small-cap life sciences firms that have yet to generate meaningful revenue from their therapeutic programmes.
Read more: Minichart
Image: Idaho National Laboratory, CC BY 2.0, via Wikimedia Commons.
